Home › Compare › INNMF vs VICI

INNMF vs VICI: Dividend Comparison 2026

INNMF yields 1081.08% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INNMF wins by $37306287.22M in total portfolio value
10 years
INNMF
INNMF
● Live price
1081.08%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37306288.18M
Annual income
$31,563,031,594,132.85
Full INNMF calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — INNMF vs VICI

📍 INNMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINNMFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INNMF + VICI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
INNMF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INNMF
Annual income on $10K today (after 15% tax)
$91,891.89/yr
After 10yr DRIP, annual income (after tax)
$26,828,576,855,012.92/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, INNMF beats the other by $26,828,576,338,743.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INNMF + VICI for your $10,000?

INNMF: 50%VICI: 50%
100% VICI50/50100% INNMF
Portfolio after 10yr
$18653144.58M
Annual income
$15,781,516,100,754.48/yr
Blended yield
84.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

INNMF
No analyst data
Altman Z
45.4
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INNMF buys
0
VICI buys
0
No recent congressional trades found for INNMF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINNMFVICI
Forward yield1081.08% ✓6.52%
Annual dividend / share$2.00 ✓$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3% ✓
Portfolio after 10y$37306288.18M ✓$966.2K
Annual income after 10y$31,563,031,594,132.85 ✓$607,376.13
Total dividends collected$36872092.59M ✓$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: INNMF vs VICI ($10,000, DRIP)

YearINNMF PortfolioINNMF Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$118,808$108,108.11$11,361$941.49+$107.4K → INNMF
2$1,327,510$1,200,385.03$13,320$1,481.32+$1.31M → INNMF
3$13,955,553$12,535,117.70$16,284$2,405.01+$13.94M → INNMF
4$138,087,992$123,155,549.73$21,040$4,071.78+$138.07M → INNMF
5$1,286,637,044$1,138,882,892.71$29,209$7,285.49+$1286.61M → INNMF
6$11,294,046,827$9,917,345,190.59$44,443$14,006.51+$11294.00M → INNMF
7$93,443,552,038$81,358,921,932.82$75,822$29,512.55+$93443.48M → INNMF
8$729,086,740,275$629,102,139,594.15$148,733$69,726.75+$729086.59M → INNMF
9$5,367,529,524,068$4,587,406,711,974.06$344,394$189,413.75+$5367529.18M → INNMF
10$37,306,288,184,886$31,563,031,594,132.85$966,234$607,376.13+$37306287.22M → INNMF

INNMF vs VICI: Complete Analysis 2026

INNMF — Stock

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Full INNMF Calculator →

VICI — REIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this INNMF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INNMF vs SCHDINNMF vs JEPIINNMF vs OINNMF vs KOINNMF vs MAININNMF vs NNNINNMF vs EPRTINNMF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.